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Introduction Theaim of this study was to assess preoperative factors associated with benign histology in 
patients undergoing surgical removal of a renal mass and to analyze outcomes of robotic partial nephrec-
tomy (PN) and radical nephrectomy (RN) for these masses.
Material and methods Overall, 2,944 cases (543 benign and 2,401 malignant) who underwent robotic PN 
and RN between 2003–2018 at 10 institutions worldwide were included. The assessment of the predictors 
of benign histology was made at the final surgical pathology report. Descriptive statistics, Mann-Whitney U,  
Pearson’s χ2, and logistic regression analysis were used.
Results Patients in the benign group were mostly female (61 vs. 33%; p <0.001), with lower body mass in-
dex (BMI) (26.0 vs. 27.1 kg/m2; p <0.001). The benign group presented smaller tumor size (2.8 vs. 3.5 cm; 
p <0.001), R.E.N.A.L. score (6.0 vs. 7.0; p <0.001). There was a lower rate of hilar (11 vs.18%; p = 0.001), 
cT≥3 (1 vs. 4.5%; p <0.001) tumors in the benign group. There was a statistically significant higher rate of 
PN in the benign group (97 vs. 86%; p <0.001) as well as a statistically significant lower 30-day re-admission 
rate (2 vs. 5%; p = 0.081). Multivariable analysis showed male gender (OR: 0.52; p <0.001), BMI (OR: 0.95; 
p <0.001), and cT3a (OR: 0.22; p = 0.005) to be inversely associated to benign histology.
Conclusions In 18% of cases, a benign histologic type was found. Only 3% of these tumors were treated 
with RN. Female gender, lower BMI, and higher T staging showed to be independent predictors of benign 
histology. 
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Variables definition
The following variables were considered:
– Baseline features: age, gender (male), body mass 
index (BMI), race (Caucasian), American Soci-
ety of Anesthesiologists (ASA) Score ≥3, diabe-
tes, hypertension, chronic kidney disease (CKD) 
≥III, pre-operative hemoglobin (Hb) and estimat-
ed glomerular filtration rate (eGFR) according 
to MDRD formula, and solitary kidney status;
– Clinical tumor staging: tumor size, R.E.N.A.L. 
Score, R.E.N.A.L. Score complexity (low, inter-
mediate, high), T stage (any), N stage (any), and 
M stage (any);
– Surgical outcomes: retroperitoneal approach rate, 
operative time (OT), estimated blood loss (EBL), 
intraoperative transfusions and complications, 
post-operative overall and major complications 
(Clavien-Dindo ≥3), length of stay (LoS), re-ad-
mission rate within 30-days, eGFR at discharge;
– Pathological outcomes: tumor size, T staging 
(T ≥3), N staging, and positive surgical margins 
(PSM).
End-point
The main outcome of the present study was the as-
sessment of the predictors of benign histology at fi-
nal surgical pathology report.
Statistical analysis
Statistical analysis was performed according to 
guidelines for reporting statistics in urology clinical 
studies [14]. It consisted of two steps. 
First, the Shapiro-Wilk test was used to establish 
data distribution. Continuous and binomial vari-
ables were reported as median and interquartile 
range (IQR) or frequencies and proportion, respec-
tively. Mann-Whitney U and Pearson’s χ2 tests were 
deemed as appropriate for the comparison among 
the two groups. 
Second, univariate and multivariate logistic regres-
sion analyses were used to evaluate the odds ratio 
(OR) and confidence intervals (CI) of the predictors 
of benign histology. According to previous evidence, 
the model included age, gender (female vs. male), 
BMI, pre-operative eGFR, R.E.N.A.L. Score (con-
tinuous), tumor hilar location, and cT staging in five 
categories (1a, 1b, 2a, 2b, and 3a) as covariates.
INTRODUCTION
Renal cell carcinoma (RCC) represents the sixth and 
the tenth most common malignancy in males and 
females, respectively [1]. The last two decades saw 
an overall increase in incidence of RCC in the US 
population, whereas mortality significantly de-
creased [2]. The incidence increase could be due to 
higher exposure to predisposing factors such as hy-
pertension, diabetes, smoking etc., as well as to the 
earlier incidental diagnosis of renal masses [3, 4]. 
The latter translated into the recommendation 
of partial nephrectomy (PN), active surveillance 
(AS), and ablation therapies as possible strategies 
for small renal masses (SRM) management [5, 6]. 
Renal biopsy, biological markers and radiologic tools 
have been assessed to characterize SRM [7]. Predic-
tors of benign histology have been investigated but 
evidence remains sparse [8]. This can have impor-
tant clinical implications such as the risk of over-
treatment [9]. Some authors raised concerns about 
the dissemination of robotic surgery favoring over-
treatment of SRM [10]. Others argued that robotic 
surgery favored the decrease of radical nephrectomy 
(RN) [11], which in many centers is still used for 
SRM [12]. On the other hand, the role of renal bi-
opsy, which could help determine histology, remains 
underused [13].
The aim of this study was to assess the factors associ-
ated to benign histology of renal masses after robotic 
surgery in a large retrospective multi-institutional 
international study and to analyze the outcomes 
of robotic PN and RN for these masses.
MATERIAL AND METHODS
After Institutional Review Board approval and data 
use agreement, clinical information of 3,479 patients 
who underwent robotic PN and RN for renal masses 
between 2003 and 2018 were collected within a ret-
rospective multi-institutional dataset. Overall, 2,944 
cases (543 benign and 2,401 malignant), performed 
at 10 large-volume tertiary institutions presented 
complete data regarding benign or malignant histol-
ogy. None of the patients included underwent pre-
operative renal biopsy. Exclusion criteria included 
genetic syndromes such as Von-Hippel Lindau dis-
ease, Bigg-Hogg-Dubé disease, tuberous sclerosis, 
bilateral renal tumors, and previous surgery for ma-
lignant renal tumor. 
Key Words: benign renal masses ‹› malignant renal masses ‹› renal cell carcinoma ‹› predictors
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All tests were two-sided and statistical significance 
was set at p <0.05. Stata® 15.0 (StataCorp 2017. Sta-
ta Statistical Software: release 15. StataCorp LLC, 
College Station, TX, USA) was used to perform sta-
tistical analysis according to the following syntax: 
swilk, ranksum, tabulate chi2, logistic.
RESULTS
Overall, 18% of patients were found to have benign 
histology at final pathology report, and 3% of them 
underwent RN. 
At baseline, there were more female patients 
in the benign group (61 vs. 33%; p <0.001), and 
this group presented a lower BMI [26.0 (23.6–29.1) 
vs. 27.1 (24.5–30.5) kg/m2; p <0.001], lower rate 
of ASA ≥3 (32 vs. 39%; p = 0.013), lower rate of dia-
betes (11 vs. 17%; p = 0.008), lower rate of hyper-
tension (37 vs. 44%; p = 0.004) and better eGFR 
[83.6 (68.0–97.1) vs. 81.0 (64.4–96.0) ml/min/1.73 m2; 
p = 0.048]. Moreover, the benign histology group 
also presented smaller tumor size [2.8 (2.0–4.3) 
vs. 3.5 (2.3–7.0) cm; p <0.001], lower R.E.N.A.L. 
score [6.0 (5.0–8.0) vs 7.0 (6.0–9.0); p <0.001], and 
lower rate of hilar (11 vs. 18%; p = 0.001), and cT ≥3 
stage (1 vs. 4.5%; p <0.001) (Table 1). 
Pathology confirmed a smaller tumor size in the 
benign group [2.8 (1.9–4.2) vs. 3.5 (2.2–6.0) cm; 
p <0.001]. 
Multivariable analysis showed male gender (OR: 
0.52; 95%CI: 0.41–0.67; p <0.001), BMI (OR: 0.95; 
95%CI: 0.93–.98; p<0.001), and cT3a (OR: 0.22; 
95%CI: 0.07, 0.63; p = 0.005) to be inversely associ-
ated with benign histology (Table 2).
DISCUSSION
The incidence of benign renal tumors among renal 
masses is around 15–30% [9, 15], and composite 
models and nomograms showed to be inconclusive 
tools to predict the rate of benign histology [16]. 
In our analysis, we found 18% of tumors to be be-
nign which is within the range established in the 
literature. Among these, most were diagnosed in 
female patients. In a retrospective study including 
135 cases, Mauermann et al. described a higher 
“female-to-male ratio” for benign renal masses 
compared to RCC (1.18:1 vs. 0.57:1; p <0.001) [17]. 
Moreover, the authors described angiomyolipoma 
to be the most frequent benign variant among fe-
males. Equally, in our analysis angiomyolipoma was 
more frequent in females (78% vs. 22%) and was 
the most common benign tumor among them: 43% 
(Table 3). On the other hand, Kim et al. found the 
prevalence of benign renal masses to be higher 
among males in a national dataset [15]. Given 
these, in our analysis, male gender showed to be 
significantly not associated with benign histology 
(OR: 0.52; p <0.001). 
We evaluated BMI as a predictor of benign histology 
as well, and we found each point of BMI decrease 
to be associated with benign histology. Epidemio-
logical data largely demonstrated the association 
of RCC with high BMI, despite the ‘obesity paradox’. 
Indeed, these patients seem to present higher inci-
dence of RCC, but less aggressive disease with better 
oncological outcomes [18]. Kava et al. retrospectively 
Table 1. Baseline features and outcomes
Variables Benign Malignant p value
Number of patients 543 (18%) 2,401 (82%)
Baseline features
Age (years) 61.0 (52.0–70.0) 61.6 (52.0–69.8) 0.745
Gender (male) 266/543 (49%) 607/2,392 (67%) <0.001
BMI (kg/m2) 26.0 (23.6–29.1) 27.1 (24.5–30.5) <0.001
ASA ≥3 154/488 (32%) 802/2,074 (39%) 0.013
Diabetes 53/462 (11%) 365/2,116 (17%) 0.008
Hypertension 169/461 (37%) 929/2,117 (44%) 0.004
CKD ≥III 28/452 (6%) 178/2,072 (9%) 0.092
Pre–operative Hb (g/dl) 13.8 (12.8–14.9) 14.1 (12.9–15.1) 0.046
Pre–operative eGFR  
(ml/min/1.73m2) 83.6 (68.0–97.1) 81.0 (64.4–96.0) 0.048
Solitary kidney 13/475 (3%) 73/1,994(4%) 0.324
Clinical tumor staging
Tumor size (cm) 2.8 (2.0–4.3) 3.5 (2.3–7.0) <0.001
R.E.N.A.L. (continuous) 6.0 (5.0–8.0) 7.0 (6.0–9.0) <0.001
R.E.N.A.L. (complexity)
Low (4–6)
Intermediate (7–9)
High (10–12)
242/457 (53%)
174/457 (38%)
41/457 (9%)
772/2,041 (38%)
864/2,041 (42%)
405/2,041 (20%)
<0.001
Tumor hilar location 46/403 (11%) 299/1,669 (18%) 0.001
cT
1a
1b
2a
2b
3a
3b
4
393/538 (73%)
80/538 (15%)
49/538 (9%)
10/538 (2%)
6/538 (1%)
–
–
1,377/2,371 (58%)
408/2,371 (17%)
379/2,371 (16%)
107/2,371 (4.5%)
95/2,371 (4%)
2/2,311 (0.2%)
3/2,311 (0.3%)
<0.001
Surgical outcomes
PN 529/543 (97%) 2,048/2,392 (86%) <0.001
Pathological outcomes
Tumor size (cm) 2.8 (1.9–4.2) 3.5 (2.2–6.0) <0.001
PSM 18/473 (4%) 103/2,346 (4%) 0.567
ASA – American Society of Anesthesiologists Score; BMI – body mass index;  
CKD – chronic kidney disease; Hb – hemoglobin; eGFR – estimated glomerular 
filtration rate; PN – partial nephrectomy; RN – radical nephrectomy; PSM – positive 
surgical margins
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Moreover, a recently published study suggested no 
difference in the incidence of benign renal tumors 
between non-hilar and hilar location (17.4 vs. 12.9%) 
suggesting no compelling rationale to perform RN 
for hilar tumors [24]. Nevertheless, in our cohort, 
RN was still mostly performed for hilar tumors 
(57 vs. 12%; p <0.001) compared to PN (data not 
shown). Overall, PN was performed for 97% and 86% 
of benign and malignant tumors, respectively. 
Given these, we noticed that 3% of RN still present 
a benign histology at final pathology report. Re-
cently, Nguyen et al. evaluated treatment trend and 
costs of benign renal masses within the National 
Inpatient Sample database. The authors identified 
7,099 benign tumors and RN still represented 44.4% 
of treatments [25]. In a multicenter retrospective 
analysis by Ljungberg et al., including 506 consecu-
tive patients diagnosed to have a benign renal tumor, 
RN was performed in 24% of cases [26]. The lower 
incidence of RN in our study might be due to the 
nature of the institutions involved, where PN repre-
sents the preferred treatment for renal masses, even 
in case of large and complex tumors [27, 28]. More-
over, this report relied only on robotic procedures, 
but laparoscopic RN is still preferred to robotic RN 
evaluated a cohort of 316 consecutive patients who 
underwent PN and achieved our same result [19]. 
Nevertheless, in our study the negative association 
between BMI increase and benign histology might 
be consequence of a selection bias, given the lower 
rate of diabetics and hypertensive patients in the 
benign group. 
Regarding tumor characteristics, the benign group 
presented less aggressive disease with smaller size, 
lower R.E.N.A.L. score, lower rate of hilar location, 
and lower clinical TNM staging. Nevertheless, only 
cT3a staging showed to present a negative associa-
tion to benign histology (OR: 0.22; p = 0.005). This 
could represent a clue for the surgeon during decision 
making, even though there are several pitfalls which 
limit radiological evaluation of renal masses [20]. 
The role of the above-mentioned covariates to pre-
dict histology is still controversial. Indeed, Kutikov 
et al. developed a nomogram which suggested the po-
tential role of R.E.N.A.L. score to predict malignant 
histology [21]. Again, in a single center study on 334 
patients with renal tumor, the association of tumor 
size and the variable N 3 (nearness) with tumor his-
tology and higher Fuhrman grade was demonstrated 
[22]. On the contrary, Antonelli et al. in a validation 
study of Kutikov’s nomogram failed to demonstrate 
the predictive role of the R.E.N.A.L. nomogram [23]. 
In all these studies tumor size was an independent 
predictor of histology, but we did not consider it as 
a covariate because this is already included in the 
R.E.N.A.L. score. It is worth noting that in this study 
hilar tumor location was not a predictor of tumor be-
nign histology. This data corroborates the findings 
made by Bauman which described lateral tumor loca-
tion as an independent predictor of benign tumor [8]. 
Variables
Univariate analysis Multivariate analysis
OR 95%CI p value OR 95%CI p value
Age 0.99 0.99, 1.00 0.514 1.00 0.98, 1.00 0.968
Gender 
Female
Male
Ref
0.47 0.39, 0.56 <0.001
Ref
0.52 0.41, 0.67 <0.001
BMI 0.96 0.94, 0.98 <0.001 0.95 0.93, 0.98 0.001
Pre-operative eGFR 1.00 0.99, 1.00 0.099 0.95 0.88, 1.03 0.722
R.E.N.A.L. Score 0.83 0.79, 0.87 <0.001 0.95 0.88, 1.03 0.256
Tumor hilar location 0.59 0.42, 0.82 <0.001 0.80 0.53, 1.20 0.282
cT
1a
1b
2a
2b
3a
Ref
0.68
0.45
0.32
0.22
0.52, 0.89
0.32, 0.62
0.17, 0.63
0.09, 0.50
0.005
<0.001
0.001
<0.001
Ref
0.79
0.77
0.60
0.22
0.55, 1.14
0.48, 1.22
0.24, 1.49
0.07, 0.63
0.214
0.276
0.272
0.005
BMI – body mass index; eGFR – estimated glomerular filtration rate; OR – odds ratio; CI – confidence interval
Table 2. Logistic regression predictors benign tumor
Table 3. Benign histology subtypes
Benign histology Female (247) Male (142) Overall (389)
Adenoma 5/5 (100%) – 5/389 (1%)
Angiomyolipoma 107/136 (78%) 29/136 (22%) 136/389 (35%)
Cystic nephroma 2/2 (100%) – 2/389 (0.5%)
Oncocytoma 98/200 (49%) 102/200 (51%) 200/389 (51%)
Others 35/46 (76%) 11/46 (24%) 46/389 (12%)
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the retrospective nature, a high risk of selection, 
blinding, and attrition bias should be considered. 
All data come from tertiary, large volume centers 
with robotic equipment and surgeons experienced 
in renal cancer management, making the results not 
applicable to every institution in reality. In addition, 
none of the centers involved performed renal biop-
sy, routinely. In our analysis, we could not account 
for detailed radiological data such as Hounsfield 
Units, which could be useful to identify benign renal 
masses characteristics [31], or the use of CT rather 
than MRI [32]. Lastly, despite the large sample size, 
the number of benign tumors is limited, thus we 
claim for future large, prospective, multicenter stud-
ies to give stronger evidences regarding this topic. 
CONCLUSIONS
In a large contemporary multicenter series of pa-
tients undergoing surgical removal of renal tumor, 
in 18% a benign histologic type was found on final 
pathology. Notably, only 3% of these tumors were 
treated with RN, which is a lower compared to previ-
ous literature. Female gender, lower BMI, and high-
er T staging showed to be independent predictors 
of benign histology. Based on our data, decision for 
surgery on benign masses may safely prioritize mini-
mally invasive PN, and should be driven by a patient 
specific and individualized assessment of competing 
causes of morbidity and mortality.
Incorporating better diagnostic tools in the future 
might help facilitate improved characterization 
of the biological potential of renal tumors and to 
avoid overtreatment.
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in many centers worldwide. Nevertheless, our find-
ings underline once again the burden of an accu-
rate pre-operative diagnosis of benign renal tumor 
to avoid surgical treatment, especially RN. Evidence 
demonstrated a paradigm shift in benign renal mass-
es treatment and renal biopsy use [13], but further 
efforts are needed to predict renal neoplasm histol-
ogy and to avoid overtreatment. Indeed, a retrospec-
tive analysis within a cohort of 542 patients who un-
derwent routine renal tumor biopsy before either PN 
or RN demonstrated that tumor biopsy reduced the 
surgery for benign neoplasms [29]. Unfortunately, 
renal mass biopsy was not routinely performed with-
in the institution involved in this study and we could 
not account for renal biopsy in this study. In addi-
tion, in the era of cost containment, surgical man-
agement of benign renal tumors represent a signifi-
cant economic effort [25]. Given these, the surgical 
management of benign renal masses is still contro-
versial and the decision to proceed to surgery should 
be individualized and based on the assessment 
of competing risks of mortality. Nevertheless, the 
non-interventional management is debated as well. 
Indeed, AS is poorly enquired for benign renal neo-
plasms, and currently data regarding long long-term 
AS of non-angiomyolipoma has short term follow-up 
and average tumor size of 2 cm or less [30]. 
However, our results could aid the surgeon to better 
understand which patient might benefit more from 
a renal biopsy before, avoiding unnecessary surgical 
treatments. 
Herein we presented one of the largest ‘real-life’ data 
analysis relying to the predictors of benign histology 
in patients with renal masses who underwent robotic 
surgery. The multicenter design and the large sam-
ple size represent the strength points; nevertheless, 
several limitations need to be acknowledged. Given 
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